China-based Hutchmed has reported data from FRUTIGA, its Phase III trial of fruquintinib alongside paclitaxel for the treatment of second-line advanced gastric 8 February 2024
Positive high-level results from the Japan Phase III trial of acoramidis in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) showed consistency to those 2 February 2024
A division of Indian generics drugmaker Glenmark Pharmaceuticals has agreed terms for a licensing deal with Chinese firms Alphamab Biopharmaceuticals and 3D Med 30 January 2024
Following on from its recent approval of Hyqvia (immune globulin) in Europe, Japanese pharma major Takeda has picked up a US approval for another CIDP product. 30 January 2024
Takeda has secured European approval for Hyqvia (immune globulin) as maintenance therapy for people with chronic inflammatory demyelinating polyneuropathy (CIDP 29 January 2024
The US supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review for patients with un 29 January 2024
Korean immuno-oncology company CanariaBio has taken a stock market battering following the failure of its Phase III trial of oregovomab, an antibody targeting C 25 January 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.